

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been sounded by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Vu 1



Section 1. Identifyin	g Information						
1. Given Name (First Name) Peter	2. Surname (Last Name) Vu	3. Date 13-November-2019					
4. Are you the corresponding au	thor? Yes No						
5. Manuscript Title Non-small cell lung cancer targetable mutations: present and future							
6. Manuscript Identifying Number PCM-2019-NSCLC-06	er (if you know it)						
Section 2. The Work	Under Consideration for Publication						
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes Vo							
Section 3. Relevant f	inancial activities outside the submitte	ed work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo							
Section 4. Intellectua	al Property Patents & Copyrights						
Do you have any patents, whe	ether planned, pending or issued, broadly rele	evant to the work? Yes V No					

Vu 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Vu has nothii	ng to disclose.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Vu 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Ident	ifying Information					
Given Name (First Name) Sandip	) 2. Surn Patel	ame (Last Name)			3. Date 13-November-2019	
4. Are you the correspondi	ng author? Yes	<b>√</b> No	Correspond Peter Vu	ling Author's Na	ame	
5. Manuscript Title Non-small cell lung canc	er targetable mutations	: present and fu	uture			
6. Manuscript Identifying N PCM-2019-NSCLC-06	lumber (if you know it)					
Section 2. The W	ork Under Consider	ation for Pub	lication			
	d work (including but not l		data monitoring		ommercial, private foundation, esign, manuscript preparation,	
Section 3. Releva	ant financial activiti	es outside the	e submitted	work.		
of compensation) with e	ntities as described in the You should report related on flicts of interest?	ne instructions. cionships that w	Use one line fo vere <b>present d</b>	r each entity;	lationships (regardless of ar add as many lines as you ne months prior to publicatio	ed by
Name of Entity	Grant	Personal N	on-Financial Support	Other? Co	mments	
AstraZeneca	<b>√</b>	√				
Bristol-Myers Squibb	<b>✓</b>	<ul><li>✓</li></ul>				
Eli Lilly	<b>✓</b>	<b>✓</b>				
Illumina		<b>✓</b>				
Rakuten		<b>✓</b>				
Tempus	✓	<b>✓</b>				
Merck	<b>✓</b>					
Pfizer	<b>✓</b>					



				1		
Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments	
Roche/Genentech	<b>✓</b>					
Fate	<b>✓</b>					
Genocea	<b>✓</b>					
lovance						
Novartis	<b>✓</b>					
Section 4. Intellectual Proper	ty Pate	nts & Cop	yrights			
Do you have any patents, whether plan	ned nendi	na or issue	d broadly releva	int to the	work?	
bo you have any paterns, whether plain	rea, perian	119 01 13340	a, broadly releva	int to the	work. Tes V Ite	
Section 5. Relationships not						
kelationships not						
Are there other relationships or activitie potentially influencing, what you wrote				influence	d, or that give the appearance of	
, ,						
Yes, the following relationships/con	ditions/circ	cumstance	s are present (exp	plain belo	w):	
✓ No other relationships/conditions/c	ircumstanc	es that pre	esent a potential	conflict o	finterest	
At the time of manuscript acceptance, jo	ournals wil	l ask autho	rs to confirm and	d, if neces	sarv. update their disclosure staten	nents.
On occasion, journals may ask authors t					• •	
Section 6. Disclosure Stateme	ent					
Based on the above disclosures, this for		matically o	renerate a disclo	cura stata	ment which will appear in the box	
below.	iii wiii aato	inatically g	gerierate a discio	suic state	ment, which will appear in the box	
Dr. Patel reports grants and personal fe	es from As	tra7eneca	grants and perso	onal fees f	rom Bristol-Myers Squibb grants a	nd
personal fees from Eli Lilly, personal fee	s from Illur	mina, perso	onal fees from Ra	kuten, gra	ants and personal fees from Tempu	ıs,
grants from Merck, grants from Pfizer, g grants from Novartis, outside the subm			nentech, grants f	from Fate	, grants from Genocea, from Iovan	ce,



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.